business news in context, analysis with attitude

The Los Angeles Times reports this morning that US Food and Drug Administration (FDA) Commissioner Mark B. McClelland said yesterday that if the practice of drug reimportation continues, it could have a detrimental effect on innovation in the biotech industry.

McClelland made the comments while visiting the California area that is home to several biotechnology companies, though he said his visit was not connected to a bill being considered by the California legislature that would have the state buying prescription medicines in Canada to save money.

According to McClelland, the legislation being considered in California "is illegal" under current US law.
KC's View: